Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. (Q38707904)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author

Martina Schmittnaegel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Nicolò Rigamonti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Yvonne Kienast

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Chia Huey Ooi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Damya Laoui

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Michele De Palma

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

6

Anna Kiialainen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Ece Kadioglu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Antonino Cassará

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Céline Wyser Rmili

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Hans-Joachim Mueller

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

language of work or name

English

0 references

publication date

1 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

Science Translational Medicine

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

Induction of angiogenesis during the transition from hyperplasia to neoplasia

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Ten years of anti-vascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

The journey from discoveries in fundamental immunology to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

The future of immune checkpoint therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

The Basis of Oncoimmunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Vascular normalization as an emerging strategy to enhance cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Targeting the tumor vasculature to enhance T cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Cancer immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Antiangiogenic resistance via metabolic symbiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Cancer Metastasis: Perivascular Macrophages Under Watch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

T lymphocyte-endothelial cell interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Active immunotherapy induces antibody responses that target tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Intertwined regulation of angiogenesis and immunity by myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAK9670

10.1126/SCITRANSLMED.AAK9670

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28404865%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference